Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|March 29, 2014
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphomaFilippo Russo, Gaetano Corazzelli, Ferdinando Frigeri, et al.
Cells|July 5, 2019
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected PatientsMaria Concetta Bellocchi, Marianna Aragri, Luca Carioti, et al.
Annals of Hematology|January 11, 2026
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?Francesco Tarantini, Corinne Contento, Ernesto Vigna, et al.
Targeted Oncology|September 25, 2023
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life ExperienceDanilo De Novellis, Raffaele Fontana, Salvatore Palmieri, et al.
European Journal of Haematology|September 16, 2025
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter StudyMaria Carmen Martorelli, Novella Pugliese, Maria Di Perna, et al.
Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
European Journal of Haematology|October 6, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsDanilo De Novellis, Daniele Derudas, Donatella Vincelli, et al.
Pageof 4